Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Hold” from Analysts

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned a consensus rating of “Hold” from the ten brokerages that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and two have issued a strong buy rating on the company.

A number of brokerages have recently commented on ZLDPF. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $44.50 on Friday. Zealand Pharma A/S has a 12-month low of $35.93 and a 12-month high of $83.12. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of 3.30 and a beta of 0.88. The business has a 50 day simple moving average of $46.43 and a 200 day simple moving average of $52.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.50. The firm had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%. On average, equities research analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.